Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 1364 results for social care

  1. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

  2. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date: TBC

  3. Multiple long-term conditions: frailty register (IND206)

    This indicator covers the practice can produce a register of people with moderate to severe frailty. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM185

  4. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

  5. NICE voluntary and community sector forum

    Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.

  6. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.

  7. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

  8. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

  9. Our partners

    NICE's partners

  10. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

    In development Reference number: GID-TA11341 Expected publication date:  02 December 2026

  11. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

  12. Help develop quality standards

    understand the areas with the greatest potential to improve the quality of care. Comment on a draft quality standard Your opportunity to...

  13. Help develop quality standards

    understand the areas with the greatest potential to improve the quality of care. Comment on a draft quality standard Your opportunity to...

  14. Research recommendations process and methods guide (PMG45)

    This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders

  15. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026